Neurofilament Light Chain Protein

Neurofilament Light Chain Protein

Introduction

[Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. PMID: 8833443

Overview

[Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain (NEFL) is a neuronal intermediate filament protein that constitutes a major component of the axonal cytoskeleton. It is one of the most extensively studied biomarkers for axonal damage in neurodegenerative diseases. NEFL is encoded by the NEFL gene (OMIM: 162280) and is expressed exclusively in [neurons](/entities/neurons), where it plays essential roles in maintaining axonal structure and caliber [1]. When axons are damaged or degenerate, NEFL is released into the cerebrospinal fluid (CSF) and blood, where it serves as a sensitive and specific marker of neuroaxonal injury [2]. The development of ultra-sensitive immunoassays (SIMOA, Ella) has enabled reliable measurement of NEFL in blood, revolutionizing its clinical utility [3].

Protein Information

Neurofilament Light Chain Protein

Introduction

[Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. PMID: 8833443

Overview

[Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain (NEFL) is a neuronal intermediate filament protein that constitutes a major component of the axonal cytoskeleton. It is one of the most extensively studied biomarkers for axonal damage in neurodegenerative diseases. NEFL is encoded by the NEFL gene (OMIM: 162280) and is expressed exclusively in [neurons](/entities/neurons), where it plays essential roles in maintaining axonal structure and caliber [1]. When axons are damaged or degenerate, NEFL is released into the cerebrospinal fluid (CSF) and blood, where it serves as a sensitive and specific marker of neuroaxonal injury [2]. The development of ultra-sensitive immunoassays (SIMOA, Ella) has enabled reliable measurement of NEFL in blood, revolutionizing its clinical utility [3].

Protein Information

{| class="infobox infox-protein"
|+ Neurofilament Light Chain Protein
\! colspan="2" | Neurofilament Light Chain (NEFL)
|-
\! Gene
| [NEFL Gene](/proteins/nefl-protein)
|-
\! UniProt ID
| [P07196](https://www.uniprot.org/uniprot/P07196)
|-
\! Molecular Weight
| 61.5 kDa
|-
\! Protein Length
| 543 amino acids
|-
\! Subcellular Localization
| Neuronal axon (cytoskeleton)
|-
\! Protein Family
| Type IV intermediate filament family
|-
\! Tissue Expression
| Exclusively in neurons (CNS and PNS)
|-
\! PDB Structure
| 1T3K, 2VT3, 5D6V
|}

Structure

NEFL is a member of the intermediate filament protein family with a characteristic tripartite structure: PMID: 27654947

Head Domain (positions 1-100)

The N-terminal head domain is non-helical and highly charged:

• Contains multiple phosphorylation sites (Ser, Thr residues) [4]
• Regulates filament assembly and interactions [5]
• Post-translational modifications affect electrophoretic mobility [6]

Rod Domain (positions 101-400)

The central α-helical rod domain is conserved across intermediate filaments:

• Contains heptad repeats forming a coiled-coil structure [7]
• Mediates dimer formation via parallel coiled-coil interactions [8]
• Essential for filament assembly [9]

Tail Domain (positions 401-543)

The C-terminal tail domain is variable in length and sequence:

• Contains multiple Lys-Ser-Pro (KSP) phosphorylation motifs [10]
• Phosphorylation regulates axonal transport and neurofilament spacing [11]
• Affects side-arm interactions between filaments [12]

Normal Function

Axonal Cytoskeleton

NEFL is a fundamental component of the axonal cytoskeleton:

• Provides structural support for neuronal processes [13]
• Forms a network that spans the entire axon [14]
• Interacts with other neurofilament subunits (NFM, NFH) [15]

Regulation of Axon Caliber

NEFL plays a critical role in determining axonal diameter:

• Cooperates with NEFM (medium chain) and NEFH (heavy chain) [16]
• Phosphorylation state modulates filament spacing [17]
• Larger axons have higher neurofilament content [18]

Transport and Organelle Positioning

Neurofilaments serve as scaffolds for cellular organelles:

• Facilitate mitochondrial distribution along axons [19]
• Support cytoskeletal organization [20]
• Interact with motor proteins for transport [21]

Role in Disease

Alzheimer's Disease (AD)

NEFL is a well-established marker of axonal injury in AD:

• CSF NEFL: Elevated in AD patients compared to controls [22]
• Blood NEFL: Increases with disease progression [23]
• Prognostic value: Predicts cognitive decline in MCI and AD [24]
• Correlation: Associates with hippocampal atrophy and cognitive scores [25]
• Combination: NEFL with [tau](/proteins/tau) provides better prognostic information [26]

Parkinson's Disease (PD)

NEFL reflects dopaminergic neuron degeneration in PD:

• CSF NEFL is elevated in PD patients, especially with dementia [27]
• Blood NEFL is increased in advanced PD [28]
• Differentiates PD from essential tremor [29]
• Correlates with disease severity (UPDRS scores) [30]

Amyotrophic Lateral Sclerosis (ALS)

NEFL is one of the most robust biomarkers in ALS:

• Markedly elevated in both CSF and blood [31]
• Diagnostic utility: Differentiates ALS from mimic disorders [32]
• Prognostic value: Higher levels predict faster progression [33]
• Monitoring: Tracks disease progression in clinical trials [34]
• Therapeutic response: Changes reflect treatment effects [35]

Multiple Sclerosis (MS)

NEFL indicates axonal injury in MS:

• Elevated in CSF during relapses [36]
• Blood NEFL predicts disability progression [37]
• Monitors treatment response in MS therapies [38]
• Differentiates MS from other neurological conditions [39]

Frontotemporal Dementia (FTD)

• Elevated NEFL in CSF correlates with disease severity [40]
• Helps differentiate FTD from AD [41]

Huntington's Disease (HD)

• Elevated in premanifest and manifest HD gene carriers [42]
• Associates with disease burden score [43]

Biomarker Utility

Clinical Applications

| Application | Utility | Evidence Level |
|-------------|---------|----------------|
| ALS diagnosis | High sensitivity and specificity | Established |
| AD progression | Prognostic biomarker | Strong |
| PD differential diagnosis | Moderate utility | Emerging |
| MS progression | Monitoring treatment response | Strong |
| FTD diagnosis |辅助诊断 | Emerging |

Assay Platforms

| Platform | Detection Limit | Clinical Use |
|----------|-----------------|--------------|
| SIMOA | ~0.5 pg/mL | Research and clinical |
| Ella | ~1 pg/mL | Clinical trials |
| ELISA | ~50 pg/mL | Research |
| ECLIA | ~10 pg/mL | Clinical |

Interpretation Guidelines

• Reference ranges: Age-dependent increases in healthy individuals [44]
• Sample type: CSF more specific, blood more practical [45]
• Longitudinal tracking: Individual baseline important [46]
• Confounding factors: Traumatic lumbar puncture, renal function [47]

Therapeutic Implications

NEFL as a biomarker informs therapeutic development:

| Approach | Utility |
|----------|--------|
| Disease-modifying therapies | Monitor treatment response |
| Neuroprotective agents | Target engagement evidence |
| Clinical trials | Enrichment and outcome measure |
| Personalized medicine | Individual risk stratification |

Key Publications

29.izzo et al. (2017) NEFL differentiates PD from ET. Neurology 89:1944-1950. PMID: 28972143(https://pubmed.ncbi.nlm.nih.gov/28972143/)

Background

The study of Neurofilament Light Chain Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. PMID: 31455949

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References